SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.,LTD.

Andere Sprachen Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Aktien

A0M4V0

CNE1000000W4

1349

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:08:35 19.04.2024			% 5 Tage	% 1. Jan.
2.08 ^HKD	0.00%		-1.42%	-18.43%

01.04.	Fudan-Zhangjiang Bio sieht Gewinn- und Umsatzrückgang im Jahr 2023	MT
28.03.	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. schlägt letzte ordentliche Dividende für das am 31. Dezember 2023 endende Geschäftsjahr vor, zahlbar am 26. August 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Fudan-Zhangjiang Bio Sees Profit, Revenue Drop in 2023	01.04.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Proposes Final Ordinary Dividend for the Year Ended December 31, 2023, Payable on August 26, 2024	28.03.
Fudan-Zhangjiang Bio's 2023 Profit Falls	26.02.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23.02.
Fudan-Zhangjiang Bio-Pharmaceutical to Subscribe for Deposit Products Worth 357 Million Yuan	04.01.
Fudan-Zhangjiang Invests 357 Million Yuan in Ping An Bank Structured Deposit Products	03.01.
Fudan-Zhangjiang Unit's Clinical Trial Application for Glioma Visualization Agent Accepted in China	27.12.
Chinese Regulator Accepts Fudan-Zhangjiang Bio-Pharmaceutical's Application for Bladder Cancer Visualization Drug Trial	18.12.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Application	18.12.
Chinese Regulator NMPA Grants Acceptance Notice for Shanghai Fudan-Zhangjiang's Investigational Drug	13.11.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug	13.11.
Fudan-Zhangjiang Bio-Pharmaceutical's Cancer Drug Passes Chinese Regulator’s Consistency Evaluation	08.11.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Notification of Approval for Supplementary Drug Application	08.11.
Fudan-Zhangjiang's Profit Drops 70.5% in Q3	31.10.23
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30.10.23
Moderate to Severe Inflammatory Acne Vulgaris Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	27.10.23
Fudan-Zhangjiang Bio Gets Nod for Cancer Drug Trial	23.10.23
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issued by the National Medical Products Administration of the PRC	20.10.23
Fudan-Zhangjiang Bio Puchases Structured Deposit Products	12.10.23
Fudan-Zhangjiang Bio Swings to Profit in H1	11.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Aktien

A0M4V0

CNE1000000W4

1349

Andere Sprachen

Filter